Abstract
Integrin receptors are considered to be the key factors in carcinogenesis. αIIbβ3-Integrin (GP IIb/IIIa) is the main glycoprotein of the surface of platelets, its presence has also been noted on the certain cancer cell lines. The molecular mechanism of its action in cancer cells remains unknown. This study presents effects of two αIIbβ3-inhibitors: Abciximab and Eptifibatide on apoptosis, expression of proline oxidase (POX), signaling molecules ERK 1/2, transcription factor NF-κB and HIF-1α, vascular endothelial growth factor (VEGF) as well as DNA biosynthesis, collagen biosynthesis and prolidase activity in MCF-7 breast cancer cells. Both ligands induced apoptosis, however we found significant differences in molecular mechanism of action between tested αIIbβ3-inhibitors. These differences include expression of POX, HIF-1α, NF-κB,VEGF and collagen biosynthesis. Eptifibatide presented stronger proapoptotic activity in MCF-7 cells than Abciximab. Results of this study suggest that Eptifibatide may be considered as a novel candidate for development of new anticancer therapy.
Keywords: αIIbβ3-integrins, αIIbβ3-inhibitors, abciximab, eptifibatide, MCF-7 breast cancer cells, apoptosis.
Current Drug Targets
Title:αIIbβ3-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells
Volume: 16 Issue: 13
Author(s): Joanna Kononczuk, Arkadiusz Surazynski, Urszula Czyzewska, Izabela Prokop, Michal Tomczyk, Jerzy Palka and Wojciech Miltyk
Affiliation:
Keywords: αIIbβ3-integrins, αIIbβ3-inhibitors, abciximab, eptifibatide, MCF-7 breast cancer cells, apoptosis.
Abstract: Integrin receptors are considered to be the key factors in carcinogenesis. αIIbβ3-Integrin (GP IIb/IIIa) is the main glycoprotein of the surface of platelets, its presence has also been noted on the certain cancer cell lines. The molecular mechanism of its action in cancer cells remains unknown. This study presents effects of two αIIbβ3-inhibitors: Abciximab and Eptifibatide on apoptosis, expression of proline oxidase (POX), signaling molecules ERK 1/2, transcription factor NF-κB and HIF-1α, vascular endothelial growth factor (VEGF) as well as DNA biosynthesis, collagen biosynthesis and prolidase activity in MCF-7 breast cancer cells. Both ligands induced apoptosis, however we found significant differences in molecular mechanism of action between tested αIIbβ3-inhibitors. These differences include expression of POX, HIF-1α, NF-κB,VEGF and collagen biosynthesis. Eptifibatide presented stronger proapoptotic activity in MCF-7 cells than Abciximab. Results of this study suggest that Eptifibatide may be considered as a novel candidate for development of new anticancer therapy.
Export Options
About this article
Cite this article as:
Kononczuk Joanna, Surazynski Arkadiusz, Czyzewska Urszula, Prokop Izabela, Tomczyk Michal, Palka Jerzy and Miltyk Wojciech, αIIbβ3-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells, Current Drug Targets 2015; 16 (13) . https://dx.doi.org/10.2174/1389450115666140804220441
DOI https://dx.doi.org/10.2174/1389450115666140804220441 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-Analgesic Effects of Opioids: The Cognitive Effects of Opioids in Chronic Pain of Malignant and Non-Malignant Origin. An Update.
Current Pharmaceutical Design Regulatory Requirements for PET Radiopharmaceuticals Production: Is Automation an Answer?
Current Medical Imaging A Functional Scaffold in Marine Alkaloid: An Anticancer Moiety for Human
Current Medicinal Chemistry SCAP/SREBPs are Central Players in Lipid Metabolism and Novel Metabolic Targets in Cancer Therapy
Current Topics in Medicinal Chemistry Cytosine Methyltransferases as Tumor Markers
Current Genomics Docking and Molecular Dynamics Study on the Inhibitory Activity of Novel Inhibitors on Epidermal Growth Factor Receptor (EGFR)
Medicinal Chemistry Meet Our Editorial Board Member
Letters in Drug Design & Discovery The Prevention and Inhibition Effect of Anthocyanins on Colorectal Cancer
Current Pharmaceutical Design Novel Agents in Anticancer Drug Therapy I (Antiangiogenic Agents, Egfr Inhibitors)
Medicinal Chemistry Reviews - Online (Discontinued) Quinoxaline Nucleus: A Promising Scaffold in Anti-cancer Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry Death Receptor Signaling in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A Review
Current Drug Metabolism Meet Our Associate Editor
Anti-Cancer Agents in Medicinal Chemistry Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Revolutionary Impact of Nanodrug Delivery on Neuroscience
Current Neuropharmacology Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents
Current Medicinal Chemistry Chronic Inflammation and Colorectal Cancer: The Role of Vascular Endothelial Growth Factor
Current Pharmaceutical Design Recent Patents on Stimuli Responsive Hydrogel Drug Delivery System
Recent Patents on Drug Delivery & Formulation Attenuation of ERK/RSK2-Driven NFκB Gene Expression and Cancer Cell Proliferation by Kurarinone, a Lavandulyl Flavanone Isolated from Sophora flavescens Ait. Roots
Endocrine, Metabolic & Immune Disorders - Drug Targets